



AHCCCS Pharmacy & Therapeutics Committee Public Testimony Form

1 message

donotreply@magellanhealth.com <donotreply@magellanhealth.com> Mon, Apr 3, 2023 at 9:57 AM
Reply-To: "AHCCCSPharmacyDept@azahcccs.gov" <AHCCCSPharmacyDept@azahcccs.gov>,
"terryj@magellanhealth.com" <terryj@magellanhealth.com>
To: AHCCCSPharmacyDept@azahcccs.gov, terryj@magellanhealth.com, troberg@alz.org

Name: Tory Roberg
Company or Organization: Alzheimer's Association Desert Southwest Chapter
Business Address: [340 E Palm Ln](#)
Business City: Phoenix
Business State: AZ
Preferred Email Address: troberg@alz.org
Phone: 6235706396
Representation: Checked
Affiliation: Unchecked
Please check the box of the statement that best applies.: I do not have a current or recent (within the last 24 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the AHCCCS P&T Committee.
If yes, name organizations and roles:: N/A
Summary of Testimony: I am writing today on behalf of the Alzheimer's Association to ask that the Arizona Pharmacy and Therapeutics (P&T) Committee make a coverage decision that allows equitable access to Medicaid coverage for Leqembi® at the next meeting. The Alzheimer's Association asks the Committee to recommend access to Leqembi that follows the U.S. Food and Drug Administration (FDA)-approved label. Each day without access to the drug, the Alzheimer's Association estimates more than 2,000 individuals aged 65 or older transition from mild dementia due to Alzheimer's to a more advanced stage of the disease where they will no longer be eligible for Leqembi. Therefore, missing the opportunity to see improved outcomes or clinical benefits at the early stages of their disease progression.
Drug/Product: Leqembi®
Therapeutic Drug Class: Monoclonal Antibodies, Anti-amyloid Beta
Testimony Format: Written

Confidentiality Notice This electronic message transmission contains information belonging to Magellan Health, its subsidiaries or affiliates, that is solely for the recipient named above and which may be confidential or privileged. MAGELLAN HEALTH, its subsidiaries or affiliates, EXPRESSLY PRESERVES AND ASSERTS ALL PRIVILEGES AND IMMUNITIES APPLICABLE TO THIS TRANSMISSION. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of this communication is STRICTLY PROHIBITED. If you have received this electronic transmission in error, please notify us at . Thank you.

